Informations sur le produit
- 1,3-Dihydro-1-[1-[[4-(6-phenyl-1H-imidazo[4,5-g]quinoxalin-7-yl)phenyl]methyl]4-piperidinyl]-2H-benzimidazol-2-one
- 1-{1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one
- 2H-benzimidazol-2-one, 1,3-dihydro-1-[1-[[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)phenyl]methyl]-4-piperidinyl]-
- 3-[1-[[4-(7-phenyl-3H-imidazo[4,5-g]quinoxalin-6-yl)phenyl]methyl]piperidin-4-yl]-1H-benzimidazol-2-one
Akti-1/2 is a potential anticancer agent that inhibits growth and induces apoptosis in cancer cells. Akti-1/2 has been shown to induce autophagy, which is the process by which cells degrade cellular components, leading to increased mitochondrial membrane potential and inhibition of cell death. Akti-1/2 also activates cyclin D2 and MCL-1 protein expression, which are important for cell cycle progression. Akti-1/2 has inhibitory properties against the proliferation of cancer cells in vitro and synergistic effects with chemical inhibitors. This drug may be useful for the treatment of eye disorders such as macular degeneration or retinitis pigmentosa.
Propriétés chimiques
Question d’ordre technique sur : 3D-FA17246 Akti-1/2
Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages